Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1Phase 1 1

Status

Completed 3Terminated 1

Sponsor Class

INDUSTRY 4OTHER 3

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 2Tumor-Agnostic 1

Conditions

Metastatic Castrate Resistant Prostate Cancer (mCRPC) 2Bites and Stings 1Adenocarcinoma 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 314atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Androgen Receptor Antagonists × Clear all
NCT04631601 2025-10-07

Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)

Amgen

Phase 1/2 Terminated
65 enrolled

Bites and Stings

NCT03899467 2024-02-12

The Safety and Tolerability of GT0918 in Subjects With mHSPC and mCRPC

Suzhou Kintor Pharmaceutical Inc,

Phase 2 Completed
61 enrolled 12 charts
Genitourinary

Metastatic Castrate Resistant Prostate Cancer (mCRPC)

NCT02987829 2021-04-23

Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients

Tracon Pharmaceuticals Inc.

Phase 1/2 Completed
72 enrolled 19 charts
Tumor-Agnostic

Adenocarcinoma

NCT02826772 2020-03-17

Safety, Tolerability, and PK of GT0918 (Proxalutamide) in Subjects With Metastatic Castrate Prostate Cancer

Suzhou Kintor Pharmaceutical Inc,

Phase 1 Completed
40 enrolled
Genitourinary

Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡